PriceTargets.com logo

NASDAQ:CRTX - Cortexyme Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $50.00
  • Forecasted Upside: 46.76 %
  • Number of Analysts: 7
  • Breakdown:
  • 2 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$34.07 As of 02/26/2021 01:00 AM ET
▲ +1.2 (3.65%)
1 month | 3 months | 12 months
Get New Cortexyme Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$50.00
▲ +46.76% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Cortexyme in the last 3 months. The average price target is $50.00, with a high forecast of $76.00 and a low forecast of $20.00. The average price target represents a 46.76% upside from the last price of $34.07.
Hold
The current consensus among 7 polled investment analysts is to hold stock in Cortexyme. This rating has held steady since November 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/6/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/4/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
1/28/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
2/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$59.00 ➝ $34.00Low
i
12/11/2020Smith Barney CitigroupInitiated CoverageSellHigh
i
12/11/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated CoverageSell$20.00High
i
12/7/2020Bank of AmericaUpgradeNeutral ➝ BuyMedium
i
9/24/2020Lifesci CapitalReiterated RatingOutperformHigh
i
Rating by D. Sherman at Lifesci Capital
6/24/2020HC WainwrightInitiated CoverageBuy$76.00High
i
Rating by A. Fein at HC Wainwright
6/2/2020Jefferies Financial GroupInitiated CoverageBuy$59.00Low
i
5/13/2020Canaccord GenuityReiterated RatingBuy$42.00 ➝ $70.00High
i
6/3/2019Credit Suisse GroupInitiated CoverageUnderperform ➝ Underperform$14.00High
i
6/3/2019Canaccord GenuityInitiated CoverageBuy ➝ Buy$42.00High
i
6/3/2019Bank of AmericaInitiated CoverageNeutral ➝ Neutral$28.00High
i
6/3/2019JMP SecuritiesInitiated CoverageMkt Outperform ➝ Mkt Outperform$53.00High
i
(Data available from 2/27/2016 forward)
Cortexyme logo
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $34.07
$32.36
$34.20

50 Day Range

MA: $36.55
$29.37
$49.21

52 Week Range

Now: $34.07
$26.66
$58.99

Volume

281,255 shs

Average Volume

306,856 shs

Market Capitalization

$1.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Cortexyme?

The following Wall Street sell-side analysts have issued stock ratings on Cortexyme in the last year: Bank of America Co., Canaccord Genuity, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, HC Wainwright, Jefferies Financial Group Inc., Lifesci Capital, Smith Barney Citigroup, and Zacks Investment Research.
View the latest analyst ratings for CRTX.

What is the current price target for Cortexyme?

4 Wall Street analysts have set twelve-month price targets for Cortexyme in the last year. Their average twelve-month price target is $50.00, suggesting a possible upside of 46.8%. HC Wainwright has the highest price target set, predicting CRTX will reach $76.00 in the next twelve months. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell has the lowest price target set, forecasting a price of $20.00 for Cortexyme in the next year.
View the latest price targets for CRTX.

What is the current consensus analyst rating for Cortexyme?

Cortexyme currently has 2 sell ratings, 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CRTX, but not buy more shares or sell existing shares.
View the latest ratings for CRTX.

What other companies compete with Cortexyme?

Other companies that are similar to Cortexyme include Cerner, Omnicell, HMS, Allscripts Healthcare Solutions, Vocera Communications, HealthStream and Computer Programs and Systems.

How do I contact Cortexyme's investor relations team?

Cortexyme's physical mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company's listed phone number is (650) 910-5717 and its investor relations email address is [email protected] The official website for Cortexyme is www.cortexyme.com.